Processing...
Clinical Trials for Kidney Cancer
Search
Search
There are 116 active trials for advanced/metastatic kidney cancer.
Click on a trial to see more information.
116 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with AML/MDS or other cancers lacking standard options are enrolled into cohorts with severe renal impairment (CLcr <30 mL/min, not on dialysis) or normal renal function to receive the approved fixed-dose oral decitabine/cedazuridine (35/100 mg) regimen. Decitabine is a DNA methyltransferase inhibitor (hypomethylating agent) and cedazuridine is a cytidine deaminase inhibitor that boosts decitabine bioavailability; the study compares pharmacokinetics and safety between renal function groups.
ClinicalTrials.gov ID: NCT04953897
TrialFetch AI summary: Adults with metastatic/unresectable melanoma (PD‑1–refractory or PD‑1–naïve) or metastatic clear‑cell RCC refractory to PD‑1/PD‑L1–based therapy receive pembrolizumab (PD‑1 blockade) combined with high‑dose aldesleukin/IL‑2 (T‑cell activation) given inpatient. Single‑arm design aims to improve objective response; excludes significant autoimmune disease, prior severe irAEs, active infection, or major cardiopulmonary compromise.
ClinicalTrials.gov ID: NCT05155033
TrialFetch AI summary: Adults with advanced/metastatic solid tumors after standard therapy receive REGN10597, an intravenously delivered anti–PD-1–IL2RA–IL2 fusion protein designed to target IL-2 signaling to PD-1–positive activated T cells while limiting systemic IL-2 effects; expansion cohorts enroll melanoma and clear-cell RCC. Key exclusions include prior IL-2/IL-15/IL-7 therapy, recent checkpoint inhibitors or systemic therapy, active immune-related AEs, significant autoimmune disease, or need for systemic immunosuppression.
ClinicalTrials.gov ID: NCT06413680
TrialFetch AI summary: Adults with advanced solid tumors refractory to standard therapy (ECOG 0–1, measurable disease) receive a single intravenous infusion of IDOV-Immune (VM-002), a genetically engineered oncolytic vaccinia virus designed for tumor-selective replication and lysis with immune-stimulating transgenes to enhance antitumor immunity. Key exclusions include prior oncolytic virus therapy, recent vaccinia/smallpox vaccination, active autoimmune disease requiring systemic therapy, significant cardiopulmonary disease, uncontrolled infection, and unstable/untreated CNS metastases.
ClinicalTrials.gov ID: NCT06910657
TrialFetch AI summary: Adults with metastatic or unresectable clear cell RCC that is CD70-positive (≥10% by IHC) after progression on at least one ICI and one TKI receive lymphodepletion (fludarabine/cyclophosphamide) followed by a single infusion of allogeneic umbilical cord blood–derived NK cells engineered with a CD70-directed CAR and IL-15, with CRISPR knockout of TGF-β receptor type II to resist TGF-β–mediated immunosuppression. Key exclusions include active infections, autoimmune disease requiring treatment, uncontrolled CNS disease, and significant organ comorbidities.
ClinicalTrials.gov ID: NCT07072234
TrialFetch AI summary: Adults with advanced/metastatic MUC1-overexpressing solid tumors: dose-escalation/expansion of M0324, an investigational MUC1-conditional CD40 agonist antibody, as monotherapy (post–standard therapy) or combined with pembrolizumab after prior ICI progression; separate cohort tests M0324 plus mFOLFIRINOX as first-line therapy for metastatic pancreatic ductal adenocarcinoma. Key exclusions include significant GI inflammation (e.g., chronic grade ≥2 diarrhea/IBD) and uncontrolled cardiovascular disease.
ClinicalTrials.gov ID: NCT07166601
TrialFetch AI summary: Adults with metastatic urothelial carcinoma: refractory cohort includes patients progressing after platinum (if eligible) and prior PD-1/L1 therapy; first-line cohort includes treatment‑naive mUC (prior perioperative therapy allowed, prior IO >6 months). Treatments are enfortumab vedotin (anti–Nectin-4 ADC with MMAE) plus sacituzumab govitecan (anti–Trop-2 ADC with SN‑38) for refractory disease, and the same doublet plus pembrolizumab (anti–PD‑1) for first line.
ClinicalTrials.gov ID: NCT04724018
TrialFetch AI summary: Enrolling adults (ECOG 0–1) with metastatic/unresectable solid tumors refractory to standard therapy (excluding melanoma, primary brain tumors/GBM, sarcoma, and pancreatic ductal adenocarcinoma; no active untreated brain mets), with expansion cohorts limited to ≤3 prior systemic lines and focused on PD-(L)1–naïve MSS colorectal cancer without liver metastases and PD-1 relapsed/refractory MSS endometrial cancer, RCC, or NSCLC. Patients receive IV ADU-1805 (anti-SIRPα mAb blocking the SIRPα–CD47 “don’t eat me” checkpoint to enhance myeloid/macrophage activity) every 3 weeks alone or with fixed-dose pembrolizumab every 3 weeks.
ClinicalTrials.gov ID: NCT05856981
TrialFetch AI summary: Enrolling adults with advanced/metastatic clear-cell or papillary renal cell carcinoma who are chronically hemodialysis-dependent (stable ≥3 months), ECOG 0–2, and have no suitable standard systemic therapy available/appropriate or have declined it (measurable disease required in the expansion cohort). Patients receive single-arm intravenous orellanine (ONC175), a synthetic mushroom-derived nephrotoxin being developed as a kidney-selective, organ-targeted RCC therapy that disrupts cellular metabolism/protein synthesis and induces tumor cell death, with dose escalation/expansion to define safety/MTD, PK, and preliminary efficacy.
ClinicalTrials.gov ID: NCT05287945
TrialFetch AI summary: Enrolling adults with locally advanced or metastatic clear cell RCC (ECOG 0–1) previously treated with standard systemic therapy—dose escalation requires ≥2 prior regimens including immunotherapy and a targeted therapy, and expansion cohorts require prior exposure to both a PD-1/L1 inhibitor and a VEGF TKI. Participants receive oral BMS-986506 monotherapy (first-in-human small molecule; target/mechanism not publicly specified) with primary focus on safety/DLTs and secondary pharmacokinetics and preliminary RECIST activity.
ClinicalTrials.gov ID: NCT07195682